The Guillain Barre Syndrome (GBS) Therapeutics Market is Forecast to Show
Stagnant Growth Until 2017
Online PR News – 03-May-2011 – – GlobalData’s analysis revealed that the global Guillain Barre Syndrome (GBS) market was worth $370m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 5.1% over the next seven years, to reach $520m by 2017. This is primarily attributed to the predicted increase in the prevalence of the disease.
At present there are only three European Medical Agency (EMEA) approved products: Kiovig (Gammagard Liquid + rHuPH20), Flebogamma (intravenous immunoglobulin (Ig)) and Privigen (intravenous Ig). These products are intravenous immunoglobulins and are marketed by Baxter Biotherapeutics (Baxter International Inc), Grifols Biologicals Inc. and CSL Behring, respectively. Several other intravenous Ig therapies are currently offered by other pharmaceutical companies. These are used as off-label treatment options for GBS and offer symptomatic relief. However, the competition is weak due to the absence of another competing class of drugs. In the US, there is no Food and Drug Administration (FDA) approved drug for GBS. However, intravenous immunoglobulins (IVIg) are prescribed as an offlabel treatment for GBS.
The global GBS therapeutics market is attractive, with a high unmet need of around 38% (approximately $141m). The high unmet need is due to the lack of adequate treatment options, difficulties in diagnosis and the low efficacy and safety profile of the available treatment options. The cost of therapy for the current treatment options is also high.
For Sample Pages, please click or add the below link to your browser:
The GBS market offers significant opportunity for the entrants with better efficacy and safety profiles. This is largely due to the fact that the current treatment options are limited to symptomatic relief. New entrants would need to focus on providing a cure for the disease in order to capture a higher share in the GBS therapeutics market. Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) are concentrating on identifying the root cause of GBS. This might lead to the development of newer
treatment options in the long term future.
GlobalData, the industry analysis specialist, has released its new report, “Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Guillain Barre Syndrome market. The report identifies the key trends shaping and driving the global Guillain Barre Syndrome market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter
the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Guillain Barre Syndrome sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782